Why is obeticholic acid not sold in China?

Obeticholic acid is a bile acid drug. Its main mechanism of action is to increase the rate of bile acid synthesis and bile acid excretion in the liver, restore bile acid circulation, increase bile entry into the digestive tract, thereby improving fat digestion and absorption. This property makes obeticholic acid highly effective in treating a range of diseases related to disorders of bile acid synthesis and excretion. For example, it can be used to treat adult patients with primary biliary cholangitis (PBC).

However, although obeticholic acid has important application value in the medical field, it is not currently available in the country and is therefore difficult to purchase in the domestic market. Obeticholic acid is a prescription drug, and its use requires strict diagnosis and prescription by a doctor. Due to its potential risks and side effects, such as abnormal liver function and gallstones, regulatory authorities have strict restrictions and regulatory requirements on its sales and use. This requires a lengthy clinical study and approval process to ensure its safety and effectiveness.

The R&D and production costs of obeticholic acid are relatively high, which also limits its popularity in the market. As an innovative drug, obeticholic acid requires a large investment in R&D funds and human resources, and its production process may also involve complex technologies and processes. This leaves the drug with a relatively high list price that may be beyond the financial reach of many patients.

In addition, market demand and the number of patients are also important factors affecting the domestic sales of obeticholic acid. If the number of domestic patients is relatively small, or market demand is insufficient to support widespread sales of the drug, manufacturers may choose not to introduce it or limit sales.